Published Online
on January 13, 2009

A more recent version of this article appeared on January 1, 2009

This Article Full Text (PDF) All Versions of this Article: 2/1/41    most recent CIRCOUTCOMES.108.832592v1 Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spatz, E. S. Articles by Desai, M. M. Search for Related Content PubMed PubMed Citation Articles by Spatz, E. S. Articles by Desai, M. M. Related Collections Related Article

Original Article

From Here to JUPITER

Identifying New Patients for Statin Therapy Using Data From the 1999–2004 National Health and Nutrition Examination Survey

Erica S. Spatz, MD; Maureen E. Canavan, MPH and Mayur M. Desai, PhD, MPH

From the Robert Wood Johnson Clinical Scholars Program (E.S.S.), Yale School of Medicine; and Division of Chronic Disease Epidemiology (M.E.C, M.M.D.), Yale School of Public Health, New Haven, Conn.

Correspondence to Erica S. Spatz, MD, Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, IE-61, 333 Cedar Street, New Haven, CT 06520-8088. E-mail erica.spatz{at}yale.edu

Background: Guidelines for statin use currently focus on patients with elevated low-density lipoprotein levels. Recent findings from the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), however, indicate that statin therapy to reduce cardiovascular risk is also effective among older persons with at-goal low-density lipoprotein but elevated high-sensitivity C-reactive protein levels. We estimate the size of and describe this new population for whom statin therapy may now be indicated based on JUPITER's findings.

Methods and Results: Using data from the 1999 to 2004 National Health and Nutrition Examination Survey, we estimate that 57.9% of older adults (men 50 years and women 60 years), or 33 547 000 (95% CI, 32 217 000 to 34 877 000) Americans, are currently taking a statin (24.4%) or indicated for statin therapy (33.5%). In addition, we estimate that 19.2%, or 11 144 000 (95% CI, 10 053 000 to 12 235 000), may become newly eligible for statin therapy. This includes 8 071 000 (13.9%; 95% CI, 7 173 000 to 8 969 000) with high-sensitivity C-reactive protein 2 mg/L and low-density lipoprotein <130 mg/dL (ie, those meeting "strict" JUPITER criteria) and an additional 3 073 000 (5.3%; 95% CI, 2 404 000 to 3 743 000) with high-sensitivity C-reactive protein 2 mg/L and low-density lipoprotein of 130 to 160 mg/dL for whom JUPITER's findings might reasonably be extended. Thus, 80% of older persons may now have an indication for statin therapy. Compared with those who would continue to have no indication for statin therapy, the JUPITER group was more likely to be female, to be older, and to have obesity, hypertension, and the metabolic syndrome.

Conclusions: JUPITER's findings have the potential to impact treatment recommendations for 20% of middle-aged to elderly adults, thus increasing the proportion of this segment of the population with an indication for statin therapy to nearly 80%.

Key Words: prevention • C-reactive • lipoprotein • epidemiology • risk factors

Related Article

From Here to JUPITER: Identifying New Patients for Statin Therapy Using Data From the 1999–2004 National Health and Nutrition Examination Survey

Erica S. Spatz, Maureen E. Canavan, and Mayur M. Desai
Circ Cardiovasc Qual Outcomes 2009 2: 41-48. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				M. A. Hlatky and P. Heidenreich The year in epidemiology, health services research, and outcomes research. J. Am. Coll. Cardiol., December 15, 2009; 54(25): 2343 - 2351. [Full Text] [PDF]

				E. Y. Yang, V. Nambi, Z. Tang, S. S. Virani, E. Boerwinkle, R. C. Hoogeveen, B. C. Astor, T. H. Mosley, J. Coresh, L. Chambless, et al. Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population Insights From the ARIC (Atherosclerosis Risk in Communities) Study. J. Am. Coll. Cardiol., December 15, 2009; 54(25): 2388 - 2395. [Abstract] [Full Text] [PDF]

				V. Vaccarino, J. D. Bremner, and M. E. Kelley JUPITER: A Few Words of Caution Circ Cardiovasc Qual Outcomes, May 1, 2009; 2(3): 286 - 288. [Full Text] [PDF]

				Statins for Everyone? Journal Watch (General), March 3, 2009; 2009(303): 4 - 4. [Full Text]

				Who Might Be Eligible to Receive Statins for Primary Prevention? Journal Watch Cardiology, February 11, 2009; 2009(211): 1 - 1. [Full Text]

				H. M. Krumholz Outcomes Research: Myths and Realities Circ Cardiovasc Qual Outcomes, January 1, 2009; 2(1): 1 - 3. [Full Text] [PDF]